Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the growth tier of the board, with significant initial trading performance [1][2]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and is recognized as an innovative enterprise [1]. - The company has developed a recombinant human albumin injection derived from rice, which is the first of its kind globally to receive regulatory approval and has begun sales [1][2]. Group 2: Financial Performance - On its first trading day, Heyuan Biotechnology opened at a price of 88 yuan per share, reflecting a 202.82% increase from the issue price of 29.06 yuan, and closed at 91.10 yuan, a total increase of 213.49% [1]. - The total amount raised from the public offering was 2.6 billion yuan, with a net amount of 2.43 billion yuan after deducting issuance costs [2]. Group 3: Use of Proceeds - The funds raised will primarily be allocated to the construction of a recombinant human albumin industrialization base, new drug research and development, and to supplement working capital [1][2]. - The company has established a production line capable of producing 1 million bottles annually and is currently building a facility expected to produce 12 million bottles of recombinant human serum albumin injection per year, which will help reduce reliance on imports [2].

Group 1: Core Views - Three companies, Xian Yicai, Heyuan Bio, and Bibet, were listed on the Shanghai Stock Exchange on October 28, marking the first batch of companies in the newly established Sci-Tech Innovation Board Growth Tier [1] - The total number of companies in the Sci-Tech Innovation Board has reached 592, with 35 in the Growth Tier, reflecting the board's commitment to supporting hard technology enterprises [1] Group 2: Heyuan Bio - Heyuan Bio's new plant in Wuhan is set to produce 120 tons of raw liquid annually, with its recombinant human serum albumin injection approved for market entry, becoming the first of its kind in China [2][3] - The company aims to revolutionize the global albumin market with its "rice blood-making" technology, which eliminates reliance on plasma extraction [4][5] - Heyuan Bio has achieved a purity level of 99.9999% for its recombinant human serum albumin, significantly improving production efficiency and safety [6][7] Group 3: Bibet - Bibet, a biopharmaceutical company focused on oncology and metabolic diseases, was also listed on the Sci-Tech Innovation Board, emphasizing its commitment to source innovation [9][10] - The company is advancing its global first-in-class drug, BEBT-908, which targets difficult-to-treat lymphoma patients, and is in the process of accelerating its clinical trials [11][12] - Bibet has developed a comprehensive platform for siRNA drug development, with multiple projects in various clinical stages, showcasing its innovative capabilities [12][13] Group 4: Xian Yicai - Xian Yicai, a key player in the semiconductor materials sector, has become the first unprofitable company to be listed on the Sci-Tech Innovation Board, highlighting the board's support for hard technology firms [17][18] - The company has achieved significant production capacity in 12-inch silicon wafers, ranking first in China and sixth globally, and aims to enhance the competitiveness of China's semiconductor industry [19][20] - Xian Yicai plans to raise 4.9 billion yuan through its IPO to expand its production capacity and accelerate technological advancements, with a goal of reaching 1.2 million wafers per month by 2026 [23][24]